CJC-1295 research guide for Ferokh. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
For anyone in Ferokh searching for CJC-1295, the key fact to understand is that this compound is available only through an online research supply market. The benefit of this online-only market is that serious vendors compete aggressively on their analytical documentation, giving researchers better verification tools than any physical store could provide. Vendors worth sourcing from make readily available batch-matched Certificates of Analysis documenting HPLC purity analysis, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the specific lot you are purchasing. This guide gives Ferokh researchers the framework to assess vendor quality rigorously and source verified-quality CJC-1295 with confidence.
CJC-1295: What the Research Shows
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Ferokh comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Evaluate CJC-1295 Vendors
Before looking at individual vendors, build a clear picture of what a proper COA looks like — so you can recognise whether a vendor meets it. When reviewing a CJC-1295 COA, verify: the batch number traces to your order, HPLC purity is ≥98%, mass spec identifies the correct molecular weight, and endotoxin levels are within acceptable research limits. For Ferokh researchers evaluating new suppliers: a modest first purchase to test the product before scaling up your order is what experienced peptide researchers consistently do. The dry lyophilised powder of CJC-1295 is always preferable to liquid pre-made solutions — lyophilised powder retains potency for years in frozen storage, while liquid preparations degrade within weeks even when refrigerated.
Order CJC-1295 — ships to Ferokh
COA-verified · International tracking · Research grade
CJC-1295 is supplied strictly for research applications and is not approved for human therapeutic use by the FDA or equivalent agencies worldwide — all information here is provided for educational purposes. Storage requirements for CJC-1295: lyophilised powder at minus 20°C, reconstituted solution refrigerated at 2-8°C and used within 30 days; reconstitute only with bacteriostatic water. The main safety concern arising from sourcing in CJC-1295 research is endotoxin from inadequately tested product — a verified endotoxin panel in the batch COA is the direct mitigation for this hazard. Researchers using CJC-1295 alongside other research compounds should examine published studies for potential interaction data before proceeding with any multi-compound protocol.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
